RPRX
$57.16-0.82%
as of close, Oct 2, 2026
☾ AH $57.16 -0.82%
Royalty Pharma plcStock · Health CareNasdaq Composite 0.05%Russell 1000 0.03%Russell 3000 0.03%MSCI World 0.02%MSCI ACWI 0.02%
RPRX SEC filings (2026)
CIK 1802768 · Pharmaceutical Preparations (SIC 2834) · incorporated in X0 · fiscal year ends in December
631 filings on EDGAR since 2020 · 6 annual, 19 quarterly, 79 current · financial statements · earnings
Latest 10-K
Feb 11, 2026
fiscal year to Dec 31, 2025
Latest 10-Q
Aug 5, 2026
quarter to Jun 30, 2026
Latest 8-K
Aug 5, 2026
Results of operations
Last earnings release
Aug 5, 2026
$1.32 vs $1.27 · ▲ 0.5%
Filings on file
631
since 2020, 390 insider forms
What happened, last 12 months#
Every earnings release with its print, every report with its quarter, the other 8-Ks by what they covered, the proxy statements, and each day an insider bought or sold — newest first, each line opening the filing on EDGAR. The index by form and year follows.
September 2026
August 2026
- Aug 18Insider saleHite Christopher (EVP & Chairman, Partnering) sold 100,000 Class A shares for $6.0M at $59.97 under a 10b5-1 plan
- Aug 13Insider saleCoyne Terrance P. (EVP & CFO) sold 11,002 Class A shares for $646K at $58.59–$59.14 under a 10b5-1 plan
- Aug 5EarningsEarnings release — EPS $1.32 vs $1.27 est. (+3.9%); revenue $674.1M (+16% y/y) 0.5%
- Aug 5ReportQuarterly report, Q2 2026 — revenue $674.1M (+16% y/y), net income $17.9M, EPS $0.04
July 2026
June 2026
- Jun 30Insider saleHite Christopher (EVP & Chairman, Partnering) sold 130,000 Class A shares for $7.3M at $56.44–$57.10 under a 10b5-1 plan
- Jun 24Insider saleUrist Marshall (EVP, Research & Investments) sold 9,098 Class A shares for $502K at $55.18 under a 10b5-1 plan
- Jun 23Insider saleHite Christopher (EVP & Chairman, Partnering) sold 150,000 Class A shares for $8.2M at $54.11–$54.47 under a 10b5-1 plan
- Jun 48-K8-K · Shareholder vote results
May 2026
- May 288-K8-K · Material definitive agreement; New financial obligation
- May 26Insider saleCoyne Terrance P. (EVP & CFO) sold 64,399 Class A shares for $3.5M at $53.98 under a 10b5-1 plan
- May 20Insider saleUrist Marshall (EVP, Research & Investments) sold 13,684 Class A shares for $722K at $52.75 under a 10b5-1 plan
- May 14Insider saleUrist Marshall (EVP, Research & Investments) sold 13,684 Class A shares for $726K at $53.06 under a 10b5-1 plan
- May 14Insider saleNorden Gregory (Director) sold 3,045 Class A shares for $161K at $53.00 under a 10b5-1 plan
- May 6EarningsEarnings release — EPS $1.30 vs $1.22 est. (+6.6%); revenue $630.6M (+11% y/y) 0.6%
- May 6ReportQuarterly report, Q1 2026 — revenue $630.6M (+11% y/y), net income $294.7M, EPS $0.67
April 2026
- Apr 28Insider saleCoyne Terrance P. (EVP & CFO) sold 34,791 Class A shares for $1.7M at $49.78 under a 10b5-1 plan
- Apr 138-K8-K · Regulation FD disclosure
- Apr 10ProxyProxy · Annual report to shareholders
- Apr 10ProxyProxy · Additional proxy materials
- Apr 10ProxyProxy · Proxy statement
- Apr 1Insider saleCoyne Terrance P. (EVP & CFO) sold 34,791 Class A shares for $1.7M at $48.33 under a 10b5-1 plan
March 2026
February 2026
- Feb 23Insider saleCoyne Terrance P. (EVP & CFO) sold 34,791 Class A shares for $1.6M at $45.32 under a 10b5-1 plan
- Feb 11EarningsEarnings release — EPS $1.46 vs $1.33 est. (+9.8%); revenue $622.0M (+5% y/y) 0.1%
- Feb 11ReportAnnual report, FY2025 — revenue $2.38B (+5% y/y), net income $770.9M, EPS $1.78
- Feb 4Insider saleCoyne Terrance P. (EVP & CFO) sold 20,163 Class A shares for $873K at $43.29 under a 10b5-1 plan
- Feb 3Insider saleCoyne Terrance P. (EVP & CFO) sold 114,954 Class A shares for $4.9M at $42.84–$42.84 under a 10b5-1 plan
- Feb 2Insider saleCoyne Terrance P. (EVP & CFO) sold 108,424 Class A shares for $4.6M at $42.08 under a 10b5-1 plan
January 2026
- Jan 30Insider saleUrist Marshall (EVP, Research & Investments) sold 20,000 Class A shares for $822K at $41.09 under a 10b5-1 plan
- Jan 23Insider saleUrist Marshall (EVP, Research & Investments) sold 20,000 Class A shares for $805K at $40.26 under a 10b5-1 plan
- Jan 20Insider saleCoyne Terrance P. (EVP & CFO) sold 69,582 Class A shares for $2.7M at $39.35 under a 10b5-1 plan
- Jan 16Insider saleUrist Marshall (EVP, Research & Investments) sold 20,000 Class A shares for $790K at $39.52 under a 10b5-1 plan
- Jan 9Insider saleUrist Marshall (EVP, Research & Investments) sold 20,000 Class A shares for $816K at $40.78 under a 10b5-1 plan
- Jan 2Insider saleCoyne Terrance P. (EVP & CFO) sold 69,582 Class A shares for $2.7M at $38.42 under a 10b5-1 plan
- Jan 2Insider saleUrist Marshall (EVP, Research & Investments) sold 20,000 Class A shares for $770K at $38.48 under a 10b5-1 plan
December 2025
- Dec 228-K8-K · Directors or officers; compensation
- Dec 228-K8-K · Regulation FD disclosure
November 2025
Insider transactions#
What officers, directors and 10% holders reported on Forms 4 and 5 over the last 13 months, from the documents themselves: one insider’s trades of one kind on one day are one row, with the shares, the price range and the total as filed. Open-market buys and sells first; awards, exercises, tax withholding, gifts and employee-plan purchases are grouped below them.
Over the last 13 months insiders sold $62.3M in 27 sales and bought nothing on the open market; 28 other transactions (awards, exercises, tax withholding, gifts and plan purchases).
| Date | Insider |
|---|---|
| Sep 28, 2026Form 4 | Urist MarshallEVP, Research & InvestmentsSold · Class A · $239K · 4,126 sh · 10b5-1 |
| Sep 22, 2026Form 4 | Hite ChristopherEVP & Chairman, PartneringSold · Class A · $5.9M · 100,000 sh · 10b5-1 |
| Aug 18, 2026Form 4 | Hite ChristopherEVP & Chairman, PartneringSold · Class A · $6.0M · 100,000 sh · 10b5-1 |
| Aug 13, 2026Form 4 | Coyne Terrance P.EVP & CFOSold · Class A · $646K · 11,002 sh · 10b5-1 |
| Jul 1, 2026Form 4 | Urist MarshallEVP, Research & InvestmentsSold · Class A · $508K · 9,099 sh · 10b5-1 |
| Jun 30, 2026Form 4 | Hite ChristopherEVP & Chairman, PartneringSold · Class A · $7.3M · 130,000 sh · 10b5-1 |
| Jun 24, 2026Form 4 | Urist MarshallEVP, Research & InvestmentsSold · Class A · $502K · 9,098 sh · 10b5-1 |
| Jun 23, 2026Form 4 | Hite ChristopherEVP & Chairman, PartneringSold · Class A · $8.2M · 150,000 sh · 10b5-1 |
| May 26, 2026Form 4 | Coyne Terrance P.EVP & CFOSold · Class A · $3.5M · 64,399 sh · 10b5-1 |
| May 20, 2026Form 4 | Urist MarshallEVP, Research & InvestmentsSold · Class A · $722K · 13,684 sh · 10b5-1 |
| May 14, 2026Form 4 | Urist MarshallEVP, Research & InvestmentsSold · Class A · $726K · 13,684 sh · 10b5-1 |
| May 14, 2026Form 4 | Norden GregoryDirectorSold · Class A · $161K · 3,045 sh · 10b5-1 |
| Apr 28, 2026Form 4 | Coyne Terrance P.EVP & CFOSold · Class A · $1.7M · 34,791 sh · 10b5-1 |
| Apr 1, 2026Form 4 | Coyne Terrance P.EVP & CFOSold · Class A · $1.7M · 34,791 sh · 10b5-1 |
| Mar 23, 2026Form 4 | Coyne Terrance P.EVP & CFOSold · Class A · $1.6M · 34,791 sh · 10b5-1 |
| Mar 2, 2026Form 4 | Coyne Terrance P.EVP & CFOSold · Class A · $1.6M · 34,791 sh · 10b5-1 |
| Feb 23, 2026Form 4 | Coyne Terrance P.EVP & CFOSold · Class A · $1.6M · 34,791 sh · 10b5-1 |
| Feb 4, 2026Form 4 | Coyne Terrance P.EVP & CFOSold · Class A · $873K · 20,163 sh · 10b5-1 |
| Feb 3, 2026Form 4 | Coyne Terrance P.EVP & CFOSold · Class A · $4.9M · 114,954 sh · 10b5-1 |
| Feb 2, 2026Form 4 | Coyne Terrance P.EVP & CFOSold · Class A · $4.6M · 108,424 sh · 10b5-1 |
| Jan 30, 2026Form 4 | Urist MarshallEVP, Research & InvestmentsSold · Class A · $822K · 20,000 sh · 10b5-1 |
| Jan 23, 2026Form 4 | Urist MarshallEVP, Research & InvestmentsSold · Class A · $805K · 20,000 sh · 10b5-1 |
| Jan 20, 2026Form 4 | Coyne Terrance P.EVP & CFOSold · Class A · $2.7M · 69,582 sh · 10b5-1 |
| Jan 16, 2026Form 4 | Urist MarshallEVP, Research & InvestmentsSold · Class A · $790K · 20,000 sh · 10b5-1 |
| Jan 9, 2026Form 4 | Urist MarshallEVP, Research & InvestmentsSold · Class A · $816K · 20,000 sh · 10b5-1 |
| Jan 2, 2026Form 4 | Coyne Terrance P.EVP & CFOSold · Class A · $2.7M · 69,582 sh · 10b5-1 |
| Jan 2, 2026Form 4 | Urist MarshallEVP, Research & InvestmentsSold · Class A · $770K · 20,000 sh · 10b5-1 |
Awards, exercises, withholding and plan purchases · 28 transactions
| Date | Insider |
|---|---|
| Sep 30, 2026Form 4 | Bassler Bonnie LDirectorAward · Class A · $37K · 642 sh |
| Aug 19, 2026Form 4 | Hite ChristopherEVP & Chairman, PartneringGift · Class A · $0 · 16,800 sh · 10b5-1 |
| Aug 7, 2026Form 4 | Legorreta Pablo G.CEO, Chairman of the Board · DirectorGift · $0 · 30,000 sh |
| Aug 7, 2026Form 4 | Coyne Terrance P.EVP & CFOGift · Class E · $0 · 18,500 sh |
| Aug 7, 2026Form 4 | Urist MarshallEVP, Research & InvestmentsGift · $0 · 3,000 sh |
| Aug 5, 2026Form 4 | Legorreta Pablo G.CEO, Chairman of the Board · DirectorAward · Class A · $0 · 65,216 sh |
| Aug 5, 2026Form 4 | Hite ChristopherEVP & Chairman, PartneringAward · Class A · $0 · 11,002 sh |
| Aug 5, 2026Form 4 | Coyne Terrance P.EVP & CFOAward · Class A · $0 · 11,002 sh |
| Aug 5, 2026Form 4 | Urist MarshallEVP, Research & InvestmentsAward · Class A · $0 · 8,252 sh |
| Jun 30, 2026Form 4 | Bassler Bonnie LDirectorAward · Class A · $37K · 689 sh |
| Jun 5, 2026Form 4 | WEATHERMAN ELIZABETH HDirectorAward · Class A · $0 · 4,545 sh |
| Jun 5, 2026Form 4 | LOVE TED WDirectorAward · Class A · $0 · 4,545 sh |
| Jun 5, 2026Form 4 | HODGSON DAVID CDirectorAward · Class A · $0 · 4,545 sh |
| Jun 5, 2026Form 4 | Norden GregoryDirectorAward · Class A · $0 · 4,545 sh |
| Jun 5, 2026Form 4 | Bassler Bonnie LDirectorAward · Class A · $0 · 4,545 sh |
| Jun 5, 2026Form 4 | Coric VladDirectorAward · Class A · $0 · 4,545 sh |
| Jun 5, 2026Form 4 | Ho CaroleDirectorAward · Class A · $0 · 4,545 sh |
| Jun 5, 2026Form 4 | Engelbert Catherine M.DirectorAward · Class A · $0 · 4,545 sh |
| May 6, 2026Form 4 | Legorreta Pablo G.CEO, Chairman of the Board · DirectorAward · Class A · $0 · 143,821 sh |
| May 6, 2026Form 4 | Hite ChristopherEVP & Vice ChairmanAward · Class A · $0 · 24,263 sh |
| May 6, 2026Form 4 | Coyne Terrance P.EVP & CFOAward · Class A · $0 · 24,263 sh |
| May 6, 2026Form 4 | Urist MarshallEVP, Research & InvestmentsAward · Class A · $0 · 18,197 sh |
| Mar 31, 2026Form 4 | Bassler Bonnie LDirectorAward · Class A · $37K · 815 sh |
| Feb 11, 2026Form 4 | Legorreta Pablo G.CEO, Chairman of the Board · DirectorAward · Class A · $0 · 157,828 sh |
| Feb 11, 2026Form 4 | Hite ChristopherEVP & Vice ChairmanAward · Class A · $0 · 26,626 sh |
| Feb 11, 2026Form 4 | Coyne Terrance P.EVP & CFOAward · Class A · $0 · 26,626 sh |
| Feb 11, 2026Form 4 | Urist MarshallEVP, Research & InvestmentsAward · Class A · $0 · 19,970 sh |
| Dec 31, 2025Form 4 | Bassler Bonnie LDirectorAward · Class A · $37K · 967 sh |
Reports and proxy statements#
Annual reports (10-K, 20-F, 40-F), quarterly reports (10-Q), current reports (8-K, 6-K) and proxy statements, newest first. An 8-K is described by its items. A form opens the document on EDGAR, or the filing’s index where it furnishes exhibits (an earnings release is the 8-K’s Exhibit 99.1).
2026 · 12 filings
| Filed | What it is |
|---|---|
| Aug 5, 202610-Q | Quarterly report, Q2 2026 — revenue $674.1M (+16% y/y), net income $17.9M, EPS $0.04 |
| Aug 5, 20268-K | Earnings release — EPS $1.32 vs $1.27 est. (+3.9%); revenue $674.1M (+16% y/y) 0.5% |
| Jun 4, 20268-K | Shareholder vote results |
| May 28, 20268-K | Material definitive agreement; New financial obligation |
| May 6, 202610-Q | Quarterly report, Q1 2026 — revenue $630.6M (+11% y/y), net income $294.7M, EPS $0.67 |
| May 6, 20268-K | Earnings release — EPS $1.30 vs $1.22 est. (+6.6%); revenue $630.6M (+11% y/y) 0.6% |
| Apr 13, 20268-K | Regulation FD disclosure |
| Apr 10, 2026ARS | Annual report to shareholders |
| Apr 10, 2026DEFA14A | Additional proxy materials |
| Apr 10, 2026DEF 14A | Proxy statement |
| Feb 11, 202610-K | Annual report, FY2025 — revenue $2.38B (+5% y/y), net income $770.9M, EPS $1.78 |
| Feb 11, 20268-K | Earnings release — EPS $1.46 vs $1.33 est. (+9.8%); revenue $622.0M (+5% y/y) 0.1% |
2025 · 30 filings
| Filed | What it is |
|---|---|
| Dec 22, 20258-K | Directors or officers; compensation |
| Dec 22, 20258-K | Regulation FD disclosure |
| Nov 5, 202510-Q | Quarterly report, Q3 2025 — revenue $609.3M (+8% y/y), net income $288.2M, EPS $0.67 |
| Nov 5, 20258-K | Earnings release — EPS $1.17 vs $1.11 est. (+5.4%); revenue $609.3M (+8% y/y) 6.8% |
| Sep 16, 20258-K | Material definitive agreement; Other events |
| Aug 13, 20258-K | Directors or officers; compensation |
| Aug 6, 202510-Q | Quarterly report, Q2 2025 — revenue $578.7M (+8% y/y), net income $32.2M, EPS $0.07 |
| Aug 6, 20258-K | Results of operations |
| Jul 17, 20258-K | Directors or officers; compensation |
| May 19, 20258-K | Material definitive agreement; Completion of an acquisition or disposition; New financial obligation; Directors or officers; compensation; Charter, bylaws or fiscal-year change |
| May 12, 20258-K | Shareholder vote results |
| May 8, 202510-Q | Quarterly report, Q1 2025 — revenue $568.2M (+0% y/y), net income $239.3M, EPS $0.55 |
| May 8, 20258-K | Results of operations |
| Apr 11, 2025DEFA14A | Additional proxy materials |
| Apr 11, 20258-K | Material definitive agreement |
| Apr 11, 2025ARS | Annual report to shareholders |
| Apr 11, 2025DEFM14A | Merger proxy statement |
| Apr 10, 2025DEFA14A | Additional proxy materials |
| Apr 10, 20258-K | Directors or officers; compensation |
| Mar 5, 2025DEFA14A | Additional proxy materials |
| Feb 13, 2025PREM14A | PREM 14A |
| Feb 12, 202510-K | Annual report, FY2024 — revenue $2.26B (−4% y/y), net income $859.0M, EPS $1.91 |
| Feb 11, 20258-K | Results of operations |
| Jan 17, 2025DEFA14A | Additional proxy materials |
| Jan 16, 2025DEFA14A | Additional proxy materials |
| Jan 13, 2025DEFA14A | Additional proxy materials |
| Jan 13, 20258-K | Regulation FD disclosure |
| Jan 10, 2025DEFA14A | Additional proxy materials |
| Jan 10, 20258-K | Material definitive agreement; Unregistered sale of equity; Regulation FD disclosure |
| Jan 10, 20258-K | Results of operations |
2024 · 21 filings
| Filed | What it is |
|---|---|
| Dec 31, 20248-K | Material definitive agreement; Charter, bylaws or fiscal-year change |
| Nov 6, 202410-Q | Quarterly report, Q3 2024 — revenue $564.7M (+5% y/y), net income $544.0M, EPS $1.21 |
| Nov 6, 20248-K | Results of operations |
| Sep 27, 20248-K | Regulation FD disclosure |
| Aug 8, 202410-Q | Quarterly report, Q2 2024 — revenue $537.3M (−0% y/y), net income $102.0M, EPS $0.23 |
| Aug 8, 20248-K | Results of operations |
| Aug 7, 20248-K | Regulation FD disclosure |
| Jun 20, 20248-K | Other events |
| Jun 10, 20248-K | Material definitive agreement; New financial obligation |
| Jun 6, 20248-K | Shareholder vote results |
| Jun 4, 20248-K | Material definitive agreement |
| May 29, 20248-K | Other events |
| May 9, 202410-Q | Quarterly report, Q1 2024 — revenue $568.0M (−17% y/y), net income $4.8M, EPS $0.01 |
| May 9, 20248-K | Results of operations |
| Apr 25, 2024ARS | Annual report to shareholders |
| Apr 25, 2024DEFA14A | Additional proxy materials |
| Apr 25, 2024DEF 14A | Proxy statement |
| Feb 15, 202410-K | Annual report, FY2023 — revenue $2.35B (+5% y/y), net income $1.13B, EPS $2.53 |
| Feb 15, 20248-K | Results of operations |
| Feb 6, 20248-K | Other events |
| Jan 8, 20248-K | Results of operations |
2023 · 18 filings — 12 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Nov 8, 202310-Q | Quarterly report, Q3 2023 — revenue $536.3M (−6% y/y), net income $72.1M, EPS $0.16 |
| Aug 8, 202310-Q | Quarterly report, Q2 2023 — revenue $538.2M (+0% y/y), net income $227.6M, EPS $0.50 |
| May 9, 202310-Q | Quarterly report, Q1 2023 — revenue $684.0M (+22% y/y), net income $340.8M, EPS $0.76 |
| Apr 27, 2023DEFA14A | Additional proxy materials |
| Apr 27, 2023DEF 14A | Proxy statement |
| Feb 15, 202310-K | Annual report, FY2022 — revenue $2.24B (−2% y/y), net income $42.8M, EPS $0.10 |
12 current reports (8-K) not listed; the year is on EDGAR.
2022 · 19 filings — 13 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Nov 8, 202210-Q | Quarterly report, Q3 2022 — revenue $573.5M (−2% y/y), net income $142.7M, EPS $0.32 |
| Aug 4, 202210-Q | Quarterly report, Q2 2022 — revenue $536.0M (−3% y/y), net income $304.5M, EPS $0.70 |
| May 5, 202210-Q | Quarterly report, Q1 2022 — revenue $562.0M (−2% y/y), net income $51.8M, EPS $0.12 |
| Apr 28, 2022DEFA14A | Additional proxy materials |
| Apr 28, 2022DEF 14A | Proxy statement |
| Feb 15, 202210-K | Annual report, FY2021 — revenue $2.29B (+8% y/y), net income $619.7M, EPS $1.49 |
13 current reports (8-K) not listed; the year is on EDGAR.
2021 · 15 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Nov 10, 202110-Q | Quarterly report, Q3 2021 — revenue $585.8M (+9% y/y), net income $101.9M, EPS $0.24 |
| Aug 11, 202110-Q | Quarterly report, Q2 2021 — revenue $555.0M (+9% y/y), net income $440.8M, EPS $1.08 |
| May 11, 202110-Q | Quarterly report, Q1 2021 — revenue $573.0M (+14% y/y), net income $69.1M, EPS $0.18 |
| Apr 29, 2021DEFA14A | Additional proxy materials |
| Apr 29, 2021DEF 14A | Proxy statement |
| Feb 24, 202110-K | Annual report, FY2020 — revenue $2.12B (+17% y/y), net income $975.0M, EPS $1.32 |
9 current reports (8-K) not listed; the year is on EDGAR.
2020 · 11 filings — 8 × 8-K, 2 × 10-Q, 1 × 8-K/A
Insider, ownership and other filings#
Insider ownership (Forms 3, 4, 5 and 144), beneficial ownership (Schedules 13D and 13G), registration and prospectus (S-1, S-3, S-8, 424B and related) and the rest, counted by year, with the newest 25 of each of the latest 3 years shown. A Form 4 is one insider’s transaction report; a 13G is a passive holder above five percent.
2026 · 86 filings — 49 × 4, 28 × 144, 3 × 13F-NT and 3 other forms
| Filed | What it is |
|---|---|
| Sep 30, 20264 | Insider transaction (Form 4) |
| Sep 30, 20264 | Insider transaction (Form 4) |
| Sep 28, 2026144 | Notice of proposed sale (Form 144) |
| Sep 24, 20264 | Insider transaction (Form 4) |
| Sep 22, 2026144 | Notice of proposed sale (Form 144) |
| Aug 19, 20264 | Insider transaction (Form 4) |
| Aug 18, 2026144 | Notice of proposed sale (Form 144) |
| Aug 17, 2026SCHEDULE 13D/A | Other filings |
| Aug 17, 20264 | Insider transaction (Form 4) |
| Aug 14, 202613F-NT | Other filings |
| Aug 13, 2026144 | Notice of proposed sale (Form 144) |
| Aug 12, 2026144 | Notice of proposed sale (Form 144) |
| Aug 12, 2026144 | Notice of proposed sale (Form 144) |
| Aug 7, 20264 | Insider transaction (Form 4) |
| Aug 7, 20264 | Insider transaction (Form 4) |
| Aug 7, 20264 | Insider transaction (Form 4) |
| Aug 7, 20264 | Insider transaction (Form 4) |
| Jul 2, 20264 | Insider transaction (Form 4) |
| Jul 2, 20264 | Insider transaction (Form 4) |
| Jul 1, 2026144 | Notice of proposed sale (Form 144) |
| Jul 1, 2026144 | Notice of proposed sale (Form 144) |
| Jun 30, 20264 | Insider transaction (Form 4) |
| Jun 25, 20264 | Insider transaction (Form 4) |
| Jun 25, 20264 | Insider transaction (Form 4) |
| Jun 24, 2026144 | Notice of proposed sale (Form 144) |
The newest 25 of 86 shown; the full year is on EDGAR.
2025 · 87 filings — 53 × 4, 9 × 144, 7 × SCHEDULE 13G/A and 12 other forms
| Filed | What it is |
|---|---|
| Dec 29, 20254 | Insider transaction (Form 4) |
| Dec 22, 20254 | Insider transaction (Form 4) |
| Dec 19, 20254 | Insider transaction (Form 4) |
| Dec 17, 20254 | Insider transaction (Form 4) |
| Dec 17, 20254 | Insider transaction (Form 4) |
| Dec 16, 2025144 | Notice of proposed sale (Form 144) |
| Dec 15, 2025144 | Notice of proposed sale (Form 144) |
| Dec 9, 20254 | Insider transaction (Form 4) |
| Dec 5, 20254 | Insider transaction (Form 4) |
| Dec 3, 20254 | Insider transaction (Form 4) |
| Dec 3, 20254 | Insider transaction (Form 4) |
| Dec 1, 2025144 | Notice of proposed sale (Form 144) |
| Dec 1, 2025144 | Notice of proposed sale (Form 144) |
| Dec 1, 2025144 | Notice of proposed sale (Form 144) |
| Nov 26, 20254 | Insider transaction (Form 4) |
| Nov 24, 2025144 | Notice of proposed sale (Form 144) |
| Nov 21, 20254 | Insider transaction (Form 4) |
| Nov 19, 2025144 | Notice of proposed sale (Form 144) |
| Nov 19, 20254 | Insider transaction (Form 4) |
| Nov 17, 2025144 | Notice of proposed sale (Form 144) |
| Nov 13, 2025SCHEDULE 13G/A | Other filings |
| Nov 7, 20254 | Insider transaction (Form 4) |
| Nov 7, 20254 | Insider transaction (Form 4) |
| Nov 7, 20254 | Insider transaction (Form 4) |
| Nov 7, 20254 | Insider transaction (Form 4) |
The newest 25 of 87 shown; the full year is on EDGAR.
2024 · 38 filings — 20 × 4, 6 × 144, 5 × SC 13G/A and 6 other forms
| Filed | What it is |
|---|---|
| Nov 8, 2024SC 13G/A | Passive holder above 5% (Schedule 13G), amended |
| Sep 30, 20244 | Insider transaction (Form 4) |
| Sep 30, 20244 | Insider transaction (Form 4) |
| Aug 12, 20244 | Insider transaction (Form 4) |
| Aug 12, 20244 | Insider transaction (Form 4) |
| Aug 12, 20244 | Insider transaction (Form 4) |
| Jul 29, 2024SC 13D/A | Active holder above 5% (Schedule 13D), amended |
| Jun 28, 20244 | Insider transaction (Form 4) |
| Jun 28, 20244 | Insider transaction (Form 4) |
| Jun 10, 20244 | Insider transaction (Form 4) |
| Jun 10, 20244 | Insider transaction (Form 4) |
| Jun 10, 20244 | Insider transaction (Form 4) |
| Jun 10, 20244 | Insider transaction (Form 4) |
| Jun 10, 20244 | Insider transaction (Form 4) |
| Jun 10, 20244 | Insider transaction (Form 4) |
| Jun 10, 20244 | Insider transaction (Form 4) |
| Jun 4, 2024424B5 | Prospectus supplement |
| Jun 3, 2024FWP | Free writing prospectus |
| Jun 3, 2024424B5 | Prospectus supplement |
| Jun 3, 2024S-3ASR | Automatic shelf registration |
| May 16, 20244 | Insider transaction (Form 4) |
| Apr 3, 2024144 | Notice of proposed sale (Form 144) |
| Apr 3, 2024144 | Notice of proposed sale (Form 144) |
| Apr 2, 20244 | Insider transaction (Form 4) |
| Apr 2, 20244 | Insider transaction (Form 4) |
The newest 25 of 38 shown; the full year is on EDGAR.
2023 · 67 filings — 44 × 4, 10 × 144, 5 × SC 13G/A and 4 other forms
Counted, not listed; the year is on EDGAR.
2022 · 73 filings — 58 × 4, 3 × SC 13D/A, 3 × SC 13G/A and 8 other forms
Counted, not listed; the year is on EDGAR.
2021 · 78 filings — 60 × 4, 3 × SC 13G, 2 × 4/A and 11 other forms
Counted, not listed; the year is on EDGAR.
2020 · 76 filings — 22 × 4, 16 × 3, 5 × CORRESP and 17 other forms
Counted, not listed; the year is on EDGAR.
About this data
Royalty Pharma plc (RPRX) has 631 filings on EDGAR going back to 2020: 6 annual reports, 19 quarterly reports and 79 current reports, plus proxy statements, insider forms and ownership schedules. Its latest annual report, a 10-K, was filed on Feb 11, 2026 for the fiscal year ended Dec 31, 2025. The most recent 8-K, on Aug 5, 2026, covered results of operations. Over the last 13 months insiders sold $62.3M in 27 sales and bought nothing on the open market; 28 other transactions (awards, exercises, tax withholding, gifts and plan purchases). Not investment advice.
Every row is a filing EDGAR lists for the registrants that have been Royalty Pharma plc, read from the SEC’s submissions index each morning; a filing accepted after that read appears the next day. Where a company changed its filing entity (a holding-company reorganisation, Google into Alphabet) the predecessor’s filings are shown for the years it filed as the company, derived from the filings themselves. Dates are the filing date; the period is the report’s own. The latest 3 years of reports are listed in full, the next years to 10 without their 8-Ks, and older years are counted; the other forms are counted too, with the newest 25 of each of the latest 3 years shown. Insider transactions are the Form 4 and Form 5 documents themselves, filed since January 2026, every number as the insider filed it: a day’s lots are summed, a blank price adds its shares and no dollars, and a purchase through an employee stock plan is a plan purchase, not insider buying. The documents stay on sec.gov, public domain, and every link opens the SEC’s copy. ChartRow does not summarise or interpret filings.
FAQ#
- Where can I read RPRX's latest 10-K?
- RPRX's latest annual report, a 10-K, was filed on Feb 11, 2026 for the fiscal year ended Dec 31, 2025. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.
- When did RPRX last file an 8-K?
- On Aug 5, 2026: results of operations. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Aug 5, 2026.
- Are RPRX insiders buying or selling?
- Over the last 13 months insiders sold $62.3M in 27 sales and bought nothing on the open market; 28 other transactions (awards, exercises, tax withholding, gifts and plan purchases). The most recent sale: Urist Marshall (EVP, Research & Investments) sold 4,126 shares on Sep 28, 2026 for $239K, under a 10b5-1 plan. Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.
- How many SEC filings has RPRX made?
- 631 filings are on EDGAR under the registrant records that have been Royalty Pharma plc, going back to 2020; 390 of them are insider ownership forms (Forms 3, 4, 5 and 144).